Peer Review History
| Original SubmissionApril 23, 2020 |
|---|
|
PONE-D-20-11696 Validation of the one-minute sit-to-stand test to measure functional exercise capacity in children and adolescents with cystic fibrosis: a multicenter randomized cross-over trial PLOS ONE Dear Dr. Combret, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Major concern has been raised by the reviewers on the sample size and the methodology of the validation process. Clarification is required on several aspects of the indicators chosen. Consider if you can respond to the criticism satisfying the reviewers' requests or if thay are so fundamental (e-g- increase sample size) not to be fulfilled in a rieasonable time frame. Please submit your revised manuscript by October 15 If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Andrea Martinuzzi Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2.Thank you for stating the following in the Competing Interests section: [I have read the journal's policy and the authors of this manuscript have the following competing interests: Prof. Bouchra Lamia reports expertise activities from Novartis, Chiesi, and from Astra Zeneca, non-financial support from Philips Respironics, grants from Lowenstein, grants from Bayer, and expertise activies from Elivie, all outside the submitted work. Mr. Tristan Bonnevie reports grants from Fisher & Paykel, outside the submitted work. All the other authors have no competing interests to declare. ]. Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf. Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Important note: This review pertains only to ‘statistical aspects’ of the study and so ‘clinical aspects’ [like medical importance, relevance of the study, ‘clinical significance and implication(s)’ of the whole study, etc.] are to be evaluated [should be assessed] separately/independently. Further please note that any ‘statistical review’ is generally done under the assumption that (such) study specific methodological [as well as execution] issues are perfectly taken care of by the investigator(s). This review is not an exception to that and so does not cover clinical aspects {however, seldom comments are made only if those issues are intimately / scientifically related & intermingle with ‘statistical aspects’ of the study}. COMMENTS: I believe that the value of ‘r’ reported in line 73 is Pearson’s Correlation coefficient [(r=0.49; p<0.01)]. In the light of the following note on Assessing Pearson’s Correlation coefficient*, conclusion given in line 76 [that ‘The STST may not be used as a complete alternative to the 6MWT’] is highly appreciated. * Statistical test usually used to assess significance of Pearson’s ‘Correlation coefficient (r)’ is ‘t’ [where t = { r � [(n-2) / (1-r2)] }for df=n-2, n is sample size] and here Ho is that the population/standard value of ‘r’ is zero. You need r=0.878 to be significant at 5% but you need r=0.273 if n=50 & you need only r=0.088 if n=500. ‘P-value’ heavily depends on sample size. Therefore, it is customary to conclude/interpret as a ‘Very strong positive correlation/association/relationship only if r = 0.70 or higher. As you can see the ‘r’ [(r=0.49; p<0.01)] value here indicates a positive association/correlation/relationship which is not very strong though highly ‘significant’ statistically. Further note that Pearson’s Correlation coefficient is not a measure of ‘Agreement/Concordance’ [instead ‘Kappa Coefficient’ (for categorical data) or ‘intra-class correlation coefficient ICC’ (for numerical/continuous data) are generally used for assessing/measuring Agreement/Concordance]. All these things are mentioned here because [according to lines 165-67: The sample size estimation showed that 36 participants were necessary to detect a correlation coefficient of 0.45 between the STST and 6MWT performances, with 80% power and an alpha level of 0.05] sample size estimation is done on the basis of detection of a correlation coefficient. Intra class correlation coefficient (ICC) were used to verify reliability [lines 182-84: Intra class correlation coefficient (ICC) were calculated using a random effects model for coherence of mean measures to verify reliability between the first and the second test for both STST and 6MWT] and not for assessing/measuring Agreement/Concordance between STST and 6MWT. Nevertheless, what is done is perfectly alright since Intra class correlation coefficient (ICC) is also a good measure of ‘reliability’. A minor suggestion: In Table 2 [Table 2. Pre- and Post-exercise test cardio-respiratory response comparisons for the STST and 6MWT in children with CF] good that both ‘Pre- and Post-exercise’ values are given (essential as description), however comparison could have been done on ‘change scores’. I think that would have been more appropriate. Is not that? I do not agree with account given in lines 307-318 that a strong correlation was found between STST and 6MWT in the 14 youngest children (≤10 years) just because r=0.60 {for above reasons}. I do not think that ‘this correlation may support the use of the STST as a first approach to functional exercise capacity assessment in children ≤10 years’. However, [as pointed out in ‘Important note’ in the beginning that] this review pertains only to ‘statistical aspects’ of the study and so ‘clinical aspects’ should be assessed separately. Further please note that any ‘statistical review’ is generally done under the assumption that (such) study specific methodological [as well as execution] issues are perfectly taken care of by the investigator(s). This review is not an exception. Reviewer #2: The study of XX and colleagues reports the sit-to-stand test as a valid and reliable tool to assess exercise capacity in children and adolescents with cystic fibrosis. Yields strengthen the assessment of STST with adequate measurement properties to assess children and adolescents with CF when 6MWT is not possible. Albeit methodology is adequate and well written, some aspects in the text remains to be confirmed. There are some points that need to be clarified: Major comments: 1. Although the aim of the study was to evaluate STST validity in children and adolescents with CF, other measures of measurement properties were performed too. To assure reader’s understanding specify the type of measurement property performed in the objective and throughout the manuscript. 2. Although sample size estimation was performed, the small sample size is one of the major issues of this study. Details about sample size calculation needs to be confirmed to assure reliability in results achieved. This calculation was performed based on a published study with CF or based on a pilot study? Please include this information and how was performed the sample size estimation. 3. Why was the second performance in STST and 6MWT used for correlation analysis? Studies and guidelines recommend using the best attempt from both tests. Authors need to review or justify this aspect. 4. Five assessors performed the assessments of STST and 6MWT in three different centers. As the assessor can influence the performance and results in the test, please specify more detailed information about the assessors and their training in the manuscript. 5. Line 222 and 223, page 12: “… results indicated that 6MWT produced a greater cardiorespiratory demand than the STST…”, indeed increase in HR and RR on 6MWT suggest this conclusion. Although, 6MWT have more time duration than STST. As well the function required in these filed tests are different. Why STST and 6MWT were used to assess the same aspect in functionality? Levy et al. (1994) demonstrated different domains in physical capacity. Authors must discuss time duration, function performance and type of domain in physical capacity required in these. Minor comments: 1. In Line 98, Page 6: The population which was observed associations of STST with other clinical outcomes need to be specified. 2. Although study procedures of STST and 6MWT was well described, more details about days, order and time of rest in other clinical outcomes performed need to be included. 3. In Line 160, Page 9: “Performance during the two rounds of both STST and the 6MWT were recorded” is confusing. Please review this phrase. 4. In statistical section, please include the information and reference used to classify intraclass correlation coefficient. 5. Only the intra-rater analysis was performed through intraclass correlation coefficient. This information must be described in statistical section and specified in the results. 6. In table 1: Please specify the measure described in range. In the statistical section the authors described the data as interquartile range. Although this information is not clear in the table. 7. Table 1 and 2: Please describe the sample size with n in lower-case letter. 8. The results showed a better correlation of STST with 6MWT in children <10 years of age. Although it is a relevant analysis, the stratification of the sample was not described in the methods and the reason for carrying out the analysis with only part of the sample was not justified. Authors must review this point. 9. Line 267, page 15: Does the term physically active refers to patients who underwent to pulmonary rehabilitation? Although pulmonary rehabilitation improve clinical outcomes, does not appears to improve physical activity. Authors should review this part of the discussion. 10. Line 309, page 17: The authors described as strong correlation was found between STST and 6MWT. Please specify the reference to classify the results of the correlation. 11. Opposite to the findings of literature in other chronic respiratory diseases and the association of sit-to-stand movement with muscle activation/strength, no correlation was found between STST and quadriceps strength. The authors should discuss this finding in the article. Reviewer #3: This is a study about the validity of sit to stand test in children with CF. It was a Multicenter study in 3 French CF Centers There are some issues that a should explored by the authors , described bellow. Introduction It is well described Method How many patients there is in the 3 French CF Centers? About that total number, how many were selected to this study? It is necessary to describe, or to add reference, about the "clinically stable participants". There is no reference for the STST. It should be there. It is necessary to describe the outcomes, fot STST and 6MWT. Heart rate, SpO2 and Borg were not discribed in the testes. Why respiratory muscles were assessed? It is not included in the study aim. The second test was used to evaluate the validity. Why not the best test? Sample size Even thought the sample was based on the expected correlation, it is known the validation study has to be, at least, 50 volunteers. The strength of quadriceps should be included as sample size estimation. CPET was assessed? It was not included in the Method, only in the Statistical section. Statistical Analysis The Bland Altman plot should be addressed. Results Quality of life, Borg, blood pressure, respiratory rate (...) were not describe in the Method Section. Table 1 is usually used to describe the population characteristics. The outcomes should be in table 2. The was follow up? Why it is written tin the flow diagram? Discussion and Conclusion In my believe, it is not possible to conclude that STST is not valid test! The sample size is not enough to guarantee it. STST has different information than 6MWT, specially for the test time. Thus, the authors should not expected to change on for other. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.
|
| Revision 1 |
|
PONE-D-20-11696R1 Measurement properties of the one-minute sit-to-stand test in children and adolescents with cystic fibrosis: a multicenter randomized cross-over trial PLOS ONE Dear Dr. Combret, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please take note and amend the last minor notes highlighted by the reviewer n°2 Please submit your revised manuscript by November 30th. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Andrea Martinuzzi Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Since the comments made on earlier draft by me (and hopefully by other respected reviewers also) are attended positively/adequately, now the manuscript is improved a lot. No major issue left, in my opinion. Reviewer #2: The authors have provided sufficient justification to my queries and have addressed most of my concerns. The manuscript improved substantially. However, I would like to suggest them to review some other aspects. 1- Line 200, Page 200: To investigate criterion validity, it is recommended to use tests that have the same characteristics and objective, and ideally are the gold standard. The authors should specify which outcomes were used to investigate criterion validity. 2- Although learning effect and intra-rater reliability was performed, they were not presented in study’s conclusion. Since validity has not been stablished, the authors should describe these results at the conclusion to support the use of 1STST. 3- Although moderate correlations were found for both analysis with the entire sample and with children≤10 years of age, the result with children≤10 years seems to have higher correlation. Was there a correlation with the sample of children>10 years age? The average age of the sample is 12 years, perhaps the characteristics of the sample have influenced the results. The authors should discuss the result in the correlation analysis with children<10 years age. 4- In line with item 3, to add information to the reader, the authors could describe in table 1 and table 2 the characteristics of the children≤10 years age. Reviewer #3: All the suggestions were accepted by the authors and the doubts were answered. The sample size was better described, and the best test was now used for the analysis. The authors were correct to better described the method and to described the outcomes, that were not performed before. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Dr. Sanjeev Sarmukaddam Reviewer #2: Yes: Camile Ludovico Zamboti Reviewer #3: Yes: Fernanda C. Lanza [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
Measurement properties of the one-minute sit-to-stand test in children and adolescents with cystic fibrosis: a multicenter randomized cross-over trial PONE-D-20-11696R2 Dear Dr. Combret, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Andrea Martinuzzi Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: As said earlier, all the comments were already attended positively/adequately, now the manuscript is improved a lot. No major issue left, in my opinion. Reviewer #2: The manuscript improved substantially and the authors have provided justification to all my queries. Reviewer #3: All the suggestions were accepted by the authors. I am happy to tell that, for me, the paper is well written and can be accepted. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Dr. Sanjeev Sarmukaddam Reviewer #2: No Reviewer #3: Yes: Fernanda C Lanza |
| Formally Accepted |
|
PONE-D-20-11696R2 Measurement properties of the one-minute sit-to-stand test in children and adolescents with cystic fibrosis: a multicenter randomized cross-over trial Dear Dr. Combret: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Andrea Martinuzzi Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .